Skip to search formSkip to main contentSkip to account menu

Low Molecular Weight Cyclin E

Known as: LMW-E 
Proteolytically processed forms of cyclin E proteins, which are specifically generated in tumors that overexpress cyclin E proteins.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (CDK2), is central to the initiation of DNA replication at the G1/S… 
2017
2017
Purpose: Preoperative aromatase inhibitor (AI) therapy has demonstrated efficacy in hormone receptor (HR)-positive postmenopausal… 
Highly Cited
2016
Highly Cited
2016
Cyclin E is altered in nearly a third of invasive breast cancers where it is a powerful independent predictor of survival in… 
2016
2016
Purpose: Low molecular weight cyclin E (LMW-E) detected by Western blot analysis predicts for reduced breast cancer survival… 
2013
2013
Expression of cyclin E proteolytic cleavage products, low-molecular weight cyclin E (LMW-E), is associated with poor clinical… 
2011
2011
Low molecular weight cyclin E (LMW-E) plays an important oncogenic role in breast cancer. LMW-E, which is not found in normal… 
Highly Cited
2010
Highly Cited
2010
Overexpression of the low molecular weight isoforms (LMW-E) of cyclin E induces chromosome instability; however, the degree to… 
Highly Cited
2010
Highly Cited
2010
Purpose: Low-molecular-weight cyclin E (LMW-E) in breast cancer cells induces genomic instability and resistance to inhibition by… 
2010
2010
The cyclin E-cyclin-dependent kinase 2 (CDK2) complex accelerates entry into the S phase of the cell cycle and promotes…